Vonoprazan-amoxicillin dual, rifabutin-based triple, and bismuth quadruple therapies for Helicobacter pylori rescue treatment: a multicentre, open-label, non-inferiority randomised trial - PubMed
4 hours ago
- #Antibiotic resistance
- #Helicobacter pylori
- #Rescue therapy
- Study compared vonoprazan-amoxicillin dual therapy (VA), rifabutin-based triple therapy (VRA), and bismuth quadruple therapy (BQT) for H. pylori rescue treatment.
- Non-inferiority of VA to BQT was not established (difference -15.0%), while VRA was non-inferior to BQT (difference -0.8%).
- Adverse events were lower in VA (8%) and VRA (25%) compared to BQT (53%).
- Amoxicillin resistance, BMI ≥25 kg/m², and smoking reduced efficacy in the VA group.
- Ten-day VRA therapy is a viable alternative to BQT with fewer adverse events, whereas VA showed unacceptable efficacy.